Somatostatin and octreotide: Physiological background and pharmacological application

Digestion

Volumn 60, Issue SUPPL. 2, 1999, Pages 2-8

  Beglinger, Christoph ^a   Drewe, Jürgen ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biological effects; Octreotide; Octreotide LAR

Indexed keywords

ANGIOPEPTIN; CHOLECYSTOKININ; GLUCAGON; GLUCOSE; INSULIN; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN RECEPTOR; VAPREOTIDE;

ABDOMINAL PAIN; AMINO ACID SEQUENCE; AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM; CHOLECYSTOKININ BLOOD LEVEL; DIARRHEA; DUODENUM; ENDOCRINE CELL; FLATULENCE; GASTROINTESTINAL TRACT; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOTHALAMUS FUNCTION; INSULIN BLOOD LEVEL; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MYENTERIC PLEXUS; NORMAL HUMAN; PANCREAS; PANCREAS ISLET; PANCREAS ISLET DELTA CELL; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; STEATORRHEA; STOMACH; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

EID: 0032923372     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051474     Document Type: Review

References (24)

1. Krulich L, Dhariwal AP, McCann SM: Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968;83: 783-790.
2. Brazeau P, Vale W, Burgus R, et al: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-79.
3. Reichlin S: Somatostatin. N Engl J Med 1983; 309:1495-1501.
4. Gillies G: Somatostatin: The neuroendocrine story. Trends Pharmacol Sci 1997;18:87-95.
5. Reichlin S: Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987;109: 320-326.
6. D'Alessio DA, Sieber C, Beglinger C, Ensinck JW: A physiologic role for somatostatin-28 as a regulator of insulin secretion. J Clin Invest 1989;84:857-862.
7. Baskin DG, Ensinck JW: Somatostatin in epithelial cells of intestinal mucosa is present primarily as somatostatin-28. Peptides 1984;5: 615-621.
8. Alumets J, Sundler F, Hakanson B: Distribution, ontogeny and ultrastructure of somatostatin immunoreactive cells in the pancreas and gut. Cell Tissue Res 1977;185:465-479.
9. Larsson LI, Goltermann N, deMagistris JF, Rehfeld JF, Schwartz TW: Somatostatin cell processes and pathways for paracrine secretion. Science 1979;205:1393-1394.
10. Reisine T: Somatostatin receptors. Am J Physiol 1995;269:G813-G820.
11. Reichlin S: Somatostatin: Historical aspects. Scand J Gastroenterol Suppl 1986;119:1-10.
12. Bloom SR, Polak JM: Somatostatin. Br Med J 1987;295:288-290.
13. Ensinck JW, Laschansky EC, Vogel RE, Simonowitz DA, Roos BA, Francis BH: Circulating prosomatostatin-derived peptides. Differential responses to food ingestion. J Clin Invest 1989;83:1580-1589.
14. Ensinck JW, Vogel RE, Laschansky EC, Francis BH: Effect of ingested carbohydrate, fat, and protein on the release of somatostatin-28 in humans. Gastroenterology 1990;98:633-638.
15. Hildebrand P, Ensinck JW, Buettiker J, et al: Circulating somatostatin-28 is not a physiologic regulator of gastric acid production in man. Eur J Clin Invest 1994;24:50-56.
16. Shoelson SE, Polonsky KS, Nakabayashi T. Jaspan JB, Tager HS: Circulating forms of somatostalin-like immunoreactivity in human plasma. Am J Physiol 1986;250:E428-E434.
17. Walsh JH: Gastrointestinal hormones: in Johnson LR (ed): Physiology of the Gastrointestinal Tract, ed 3. New York. Raven Press, 1994, pp 1-30.
18. Hildebrand P, Ensinck JW, Gyr K, et al: Evidence for hormonal inhibition of exocrine pancreatic function by somatostatin-28 in humans. Gastroenterology 1992;103:240-247.
19. Harris AG: Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects. Gut 1994;35(suppl):1-4.
20. Gyr KE, Meier R: Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Digestion 1993;54(suppl 1):14-19.
21. Mottet C, Sieber CC, Nauer A, et al: Hemodynamic effects of the somatostatin analog lanreotide in humans: Placebo-controlled, cross-over dose-ranging echo-Doppler study. Hepatology 1998;27:920-925.
22. Flogstad AK, Halse J, Haldorsen T, et al: Sandostatin LAR in acromegalic patients: A dose-range study. J Clin Endocrinol Metab 1995;80: 3601-3607.
23. Grass P, Marbach P, Bruns C, Lancranjan I: Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationships. Metabolism 1996;45(suppl 1):27-30.
24. Gillis JC, Noble S, Goa KL: Octreotide long-acting release. A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-699.